What Cantabio Pharmaceuticals Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Toth Gergely | Chief Executive Officer | Sep 12 | Grant / award · A | +7,352,941 | — | — | 23,432,088 |
| Toth Gergely | Chief Executive Officer | Apr 01 | Grant / award · A | +3,600,000 | — | — | 16,079,147 |
| Toth Gergely | Chief Executive Officer | Mar 27 | Grant / award · A | +2,400,000 | — | — | 12,479,147 |
| Toth Gergely | Chief Executive Officer | Dec 17 | Grant / award · A | +10,079,147 | — | — | 10,079,147 |
| Toth Gergely | Chief Executive Officer | Dec 17 | Disposition to Issuer · D | −13,500,000 | — | — | 0 |
Loading...
